nach oben

Current Dermatology Reports

Erschienen in:

18.01.2019 | Psoriasis (J Wu, Section Editor)

Update on Risankizumab for Psoriasis

verfasst von: Jennifer C. Bares, Mark G. Lebwohl

Erschienen in: Current Dermatology Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review highlights the latest data on risankizumab, including efficacy and safety data from recent clinical trials.

Recent Findings

In multiple phase 3 clinical trials, risankizumab was shown to be safe and efficacious. Risankizumab demonstrated superior efficacy to leading active comparators for the induction and maintenance of clear skin and was shown to have a safety profile similar to other biologic therapies currently on the market.

Summary

Targeted biologic medications for plaque psoriasis have provided insight into the complex immune pathways that are now understood to lead to the development of several autoimmune diseases including plaque psoriasis. Risankizumab, a novel, fully human monoclonal antibody against the IL-23p19 subunit, is currently under investigation for the treatment of moderate-to-severe plaque psoriasis and shows promise to provide complete and lasting skin clearance with convenient dosing for patients. Future studies are needed to explore the long-term safety and efficacy of risankizumab beyond 5 years of therapy.

Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81.CrossRef

Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.CrossRef

Pfohler C, Muller CS, Vogt T. Psoriasis vulgaris and psoriasis pustulosa - epidemiology, quality of life, comorbidities and treatment. Curr Rheumatol Rev. 2013;9(1):2–7.CrossRef

Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12):1664–75.CrossRef

Lebwohl MG. Biologics for psoriasis: a translational research success story. J Invest Dermatol. 2015;135(5):1205–7.CrossRef

Torres T. Selective interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on Risankizumab. Drugs. 2017;77(14):1493–503.CrossRef

Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–34.CrossRef

Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–15.CrossRef

Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5.

10.

• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7 This study demonstrated that risankizumab was well tolerated and associated with substantial clinical response at week 12 compared with placebo. CrossRef

11.

•• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017;376(16):1551–60 This study showed that risankizumab was well tolerated and associated with a clinical response superior to ustekinumab at 12 weeks. CrossRef

12.

•• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61 This study demonstrated the efficacy of risankizumab is more rapid and superior to that of ustekinumab through 1 year while having a similar safety profile and equally convenient dosing. CrossRef

13.

Abbvie. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 trials. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantlygreater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm. Published 26 October 2017. Accessed 30 August 2018.

14.

Abbvie. Risankizumab meets all primary endpoints reporting positive results in fourth pivotal phase 3 psoriasis study. https://news.abbvie.com/news/press-releases/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasisstudy.htm. Published 4 December 2017. Accessed 30 August 2018.

15.

Abbvie. Abbvie submits biologics license application to U.S. FDA for investigational treatment risankizumab for moderate to severe plaque psoriasis. https://news.abbvie.com/news/abbvie-submits-biologics-license-application-to-us-fda-for-investigational-treatment-risankizumab-for-moderate-to-severeplaque-psoriasis.htm. Published 25 April 2018. Accessed 30 August 2018.

16.

Feagan BG, Sandborn WJ, D'haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709.CrossRef

17.

Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–302.CrossRef

18.

Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.CrossRef

19.

Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.CrossRef

Titel: Update on Risankizumab for Psoriasis
verfasst von: Jennifer C. Bares
Mark G. Lebwohl
Publikationsdatum: 18.01.2019
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 1/2019
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-019-0250-4

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen